Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Federal Trade Commission
Citi
US Department of Justice
Mallinckrodt
Fuji
Cantor Fitzgerald
Harvard Business School
Healthtrust
Accenture

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,301,238

« Back to Dashboard

Which drugs does patent 8,301,238 protect, and when does it expire?


Patent 8,301,238 protects IONSYS and is included in one NDA.

This patent has seventy-one patent family members in eighteen countries.

Summary for Patent: 8,301,238

Title:Two-part electrotransport device
Abstract: A switch operated therapeutic agent delivery device is described. The device comprises two parts, which are assembled by a user prior to use. A first part contains a power supply and circuitry for the device; and a second part comprises electrodes and reservoirs containing the therapeutic agent to be delivered. The action of combining the two parts of the device causes the two parts to be irreversibly coupled together, completes an electrical connection between the two parts, and closes one or more switches, thereby connecting a power source, such as a battery, into the device's circuitry, thereby powering the device on so that it is ready for use. The device can then be attached to a patient, who can operate the device by pressing a button in a proper sequence.
Inventor(s): Netzel; Zita S. (Los Altos, CA), Lemke; John (Pleasanton, CA), Seward; David (Seattle, WA), Read; Brian W. (Brier, WA), White; Bradley E. (Mason, OH), Chen; Corinna X. (Oakland, CA), Hayter; Paul (Mountain View, CA)
Assignee: Incline Therapeutics, Inc. (Redwood City, CA) Alza Corporation (Vacaville, CA)
Application Number:13/250,031
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
The Medicines Co
IONSYS
fentanyl hydrochloride
SYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,301,238

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,364,656Method of storing an electrotransport drug delivery device► Subscribe
8,428,708Self-test for analgesic product► Subscribe
8,781,571Switch validation circuit and method► Subscribe
9,095,706Self-test for analgesic product► Subscribe
9,645,179Self-test for analgesic product► Subscribe
8,428,709Current control for electrotransport drug delivery► Subscribe
9,731,121Switch validation circuit and method► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,301,238

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2013266914► Subscribe
Australia2013274873► Subscribe
Australia2015271708► Subscribe
Brazil112013024783► Subscribe
Brazil112013025000► Subscribe
Canada2828613► Subscribe
Canada2828617► Subscribe
Canada2873425► Subscribe
Canada2874983► Subscribe
Canada2949709► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
AstraZeneca
Queensland Health
Express Scripts
Accenture
Mallinckrodt
Merck
Colorcon
Cantor Fitzgerald
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot